Lack of Risk Info on Exhibit Panel Nets Untitled Letter

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

By signing up for a tour of the Thompson FDA Compliance Expert Suite, you are also registering to receive email offers and product updates from us. Simply click unsubscribe at the bottom of any email if you would like to discontinue delivery.

Alleged Lack of Risk Info on Exhibit Panel Nets Untitled Letter

J.W. Schomisch

March 7, 2025 at 03:12 PM EST

The FDA’s Office of Prescription Drug Promotion (OPDP) sent Dexcel Pharma USA an Untitled Letter Feb. 3 over an exhibit booth panel promoting Hemady (dexamethasone tablets) for oral use. OPDP alleged the exhibit panel made false or misleading claims and representations about the risks and benefits of Hemady. The FDA had reviewed the promotional communication under cover of Fo... Read More

My Research Folders

You are not Logged in yet, Please login to see Your research folders.

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

Alleged Lack of Risk Info on Exhibit Panel Nets Untitled Letter

My Research Folders

THOMPSON FDA

COMPLIANCE EXPERT

RESOURCES

HELP

CONTACT